AMCo Amdipharm Mercury Pharmaceuticals

About us

Concordia International is part of the Concordia International Corp, a specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines [please see our Corporate website here]. We have a strong international footprint and supply a diversified portfolio of more than 200 well-established off-patent molecules to patients, partners and healthcare authorities in more than 90 countries [see our Medicines here]. We have an extensive Environmental, Social & Governance programme [see here]

Read more

Latest News

  • 19/07/2018: Concordia International Corp. Announces NASDAQ Delisting

    Concordia International Corp. today announced that as a result of the Company's decision not to submit a plan to regain compliance with NASDAQ Global Select Market's ("Nasdaq") continued listing requirements, which decision was announced by Concordia in a press release on May 31, 2018, Nasdaq announced yesterday its determination to delist the Company's securities from Nasdaq.
  • 17/07/2018: Recruitment Scams

    Recent incidents have occurred involving person(s) falsely claiming to recruit on behalf of Concordia. Please note that Concordia or its group/subsidiary companies does not (nor do any of the organizations that recruit on our behalf) permit any unauthorized recruitment and in the process do not seek or provide money or payments

More news

More news


"Concordia International is part of the Concordia International Corp, a diverse international company focused on legacy pharmaceutical products and orphan drugs. We have a number of product ranges, including Concordia products, Amdipharm products, Mercury Pharma products, Abcur products, BnM products and Focus Pharma products. For more information please visit our Products page."

Our Products